Previously, although these therapies did not reach clinical availability, P2X7 antagonists have been investigated as a treatment for rheumatoid arthritis [75,76] and, more promisingly, Crohn’s disease [77], which found the P2X7 inhibitors to be safe and well tolerated. The gene discussed is P2RX7; the disease is rheumatoid arthritis.